UK MND RI collaborative partner LifeArc held a webinar on Drug Repurposing for MND on Monday 5th February to discuss the need for better repurposed treatment options for people living with MND, and to share information about an open funding call for The Motor Neuron Disease Translational Challenge: a multi-million-pound programme developed by LifeArc, aiming to accelerate MND research by fast-tracking scientific discoveries into new clinical solutions to transform how MND is detected, treated, and managed.

Professor Christopher McDermott, UK MND RI co-director and co-lead of EXPERTS-ALS, joined the webinar panel which discussed a shared vision to transform the way in which potential MND therapies are assessed so that only the most promising candidates make it into clinical trials. Professor McDermott presented on the EXPERTS-ALS drug prioritisation platform, discussing the drug repurposing landscape within MND and outlining how platforms such as EXPERTS-ALS may be a potential translational route for successful pre-clinical projects funded via this new grant.

Professor Martin Turner, UK MND RI Programme Lead and co-lead of EXPERTS-ALS, said “The story for the last 30 years has been too many failed trials with too little biomarker data to help improve future trials. The best predictor of a drug having benefit for human MND is a human biomarker of disease-slowing. EXPERTS-ALS offers the hope of identifying the most promising drugs to put into trials by using a biomarker-led experimental medicine screening approach. This UK-wide platform will allow screening of smaller groups of people living with MND to give a more rapid ‘go’ or ‘no go’ to putting a candidate drug forward for testing in a placebo-controlled trial.”

Listen to the full webinar here.